利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.025 秒)

    Methods For Producing Dendritic Cells That Have Acquired Ctl-Inducing Ability
    1.
    发明申请
    Methods For Producing Dendritic Cells That Have Acquired Ctl-Inducing Ability 审中-公开
    生产获得Ctl诱导能力的树突状细胞的方法

    公开(公告)号：US20080194020A1

    公开(公告)日：2008-08-14

    申请号：US11574641

    申请日：2005-09-02

    申请人： Jun Imai ,  Mikako Maruya ,  Shigeo Koyasu ,  Hironori Hasegawa ,  Ichiro Yahara

    发明人： Jun Imai ,  Mikako Maruya ,  Shigeo Koyasu ,  Hironori Hasegawa ,  Ichiro Yahara

    IPC分类号： C12N5/06 ,  C07K14/435 ,  C07H21/04 ,  C12N15/63

    CPC分类号： C12N5/0639 ,  C12N2501/07

    摘要： The present inventors worked on elucidating the mechanism of antigen cross-presentation by dendritic cells, and revealed that foreign antigens taken up in dendritic cells are degraded by proteasomes after undergoing polyubiquitination. Based on the novel finding that polyubiquitination is involved in cross-presentation, the promotion of polyubiquitination was attempted by a number of methods, and the promotion of antigen presentation was confirmed. These methods enable the production of dendritic cells effective for inducing CTL activation.

    摘要翻译： 本发明人致力于阐明树突状细胞抗原交叉呈递的机理，并揭示在经历多聚泛素化后，被树突状细胞吸收的外源抗原被蛋白酶体降解。 基于多泛素化涉及交叉表达的新发现，通过多种方法尝试促进多泛素化，证实了抗原呈递的促进作用。 这些方法能够产生有效诱导CTL活化的树突状细胞。

    Methods for Selecting Proteins that are Readily Presented as Antigens on Dendritic Cells
    2.
    发明申请
    Methods for Selecting Proteins that are Readily Presented as Antigens on Dendritic Cells 审中-公开
    选择易于树突状细胞抗原的蛋白质的选择方法

    公开(公告)号：US20080064048A1

    公开(公告)日：2008-03-13

    申请号：US11574612

    申请日：2005-09-02

    申请人： Jun Imai ,  Mikako Maruya ,  Shigeo Koyasu ,  Hironori Hasegawa ,  Ichiro Yahara

    发明人： Jun Imai ,  Mikako Maruya ,  Shigeo Koyasu ,  Hironori Hasegawa ,  Ichiro Yahara

    IPC分类号： G01N33/567 ,  C12N5/02

    CPC分类号： C12N5/0639 ,  G01N33/5047

    摘要： The present inventors worked on elucidating the mechanism of antigen cross-presentation by dendritic cells, and revealed that foreign antigens taken up in dendritic cells are degraded by proteasomes after undergoing polyubiquitination. They discovered a positive correlation between the uptake amount of an antigenic protein by dendritic cells or the level of polyubiquitination and the level of antigen presentation of the antigenic protein. Based on these findings, methods were developed for predicting the intensity of cross-presentation of an anti genic protein by measuring the amount of antigenic protein taken up or polyubiquitinated protein. The use of these methods allows selecting antigenic proteins that are readily presented as antigens from among a number of proteins. The methods of the present invention enable suitable cancer immune vaccines to be provided through selection of more suitable cancer-specific proteins.

    摘要翻译： 本发明人致力于阐明树突状细胞抗原交叉呈递的机理，并揭示在经历多聚泛素化后，被树突状细胞吸收的外源抗原被蛋白酶体降解。 他们发现树突状细胞的抗原蛋白摄取量或多聚泛素化水平与抗原蛋白的抗原呈递水平呈正相关。 基于这些发现，开发了通过测量抗原蛋白摄取或多聚泛素化蛋白的量来预测抗基因蛋白的交叉表达强度的方法。 使用这些方法允许从许多蛋白质中选择容易呈现为抗原的抗原蛋白质。 本发明的方法通过选择更合适的癌症特异性蛋白质来提供合适的癌症免疫疫苗。

    Methods for selecting candidate peptides presented on the surface of cancer cells following their binding to MHC class I molecules
    3.
    发明申请
    Methods for selecting candidate peptides presented on the surface of cancer cells following their binding to MHC class I molecules 审中-公开
    选择在与MHC I类分子结合后，癌细胞表面呈现的候选肽的方法

    公开(公告)号：US20090280511A1

    公开(公告)日：2009-11-12

    申请号：US12313855

    申请日：2008-11-25

    申请人： Ichiro Yahara ,  Shigeo Koyasu ,  Jun Imai

    发明人： Ichiro Yahara ,  Shigeo Koyasu ,  Jun Imai

    IPC分类号： G01N33/574 ,  G06G7/60

    CPC分类号： G01N33/5011 ,  G01N2333/70539

    摘要： An objective of the present invention is to provide methods for selecting candidate peptides presented on the surface of cancer cells following binding to MHC class I molecules, wherein the peptides are involved in the stimulation of T cell immunity (cellular immunity). The present inventors discovered a new principle of MHC I-mediated antigen presentation in which a T cell antigen epitope is more efficiently presented on MHC I molecules when it is positioned at the N-terminal side than when positioned at the C-terminal side.

    摘要翻译： 本发明的目的是提供用于选择在与MHC I类分子结合之后呈现在癌细胞表面上的候选肽的方法，其中所述肽参与T细胞免疫（细胞免疫）的刺激。 本发明人发现了MHC I介导的抗原呈递的新原理，其中当位于N末端侧时，当位于C末端侧时，T细胞抗原表位在MHC I分子上更有效地呈现。

    Inflammatory Cytokine Inhibitors
    4.
    发明申请
    Inflammatory Cytokine Inhibitors 审中-公开
    炎症细胞因子抑制剂

    公开(公告)号：US20070280950A1

    公开(公告)日：2007-12-06

    申请号：US10586406

    申请日：2005-01-19

    申请人： Ayako Okabe ,  Shingo Toji ,  Yoshiro Kishi ,  Ichiro Yahara

    发明人： Ayako Okabe ,  Shingo Toji ,  Yoshiro Kishi ,  Ichiro Yahara

    IPC分类号： A61K39/395 ,  A61K45/00 ,  A61P29/00 ,  C07K16/28 ,  C12N15/13 ,  C12N15/63 ,  G01N33/15 ,  G01N33/53

    CPC分类号： C07K16/2848 ,  A61K2039/505 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/6863

    摘要： A search was conducted for functional antibodies that endogenously regulate cytokines, focusing on the relationship between inflammatory diseases and cytokines. Mice were immunized with a human peripheral blood monocyte fraction and the obtained antibodies were examined for a cytokine-regulating effect. As a result, of these antibodies, antibody #33 was confirmed to inhibit the production of numerous typical inflammatory cytokines. When, at the same time, the promoting effect of antibody #33 on IL-10 production was examined, it was revealed that antibody #33 has an effect of accelerating IL-10 production but no activity to induce an excessive IL-10 production. The antigen of this promising antibody was verified to be CD61. Therefore, it is conceivable that when anti-CD61 antibodies are applied to the treatment of inflammatory diseases, they would become pharmaceuticals with both a definite efficacy and a high safety.

    摘要翻译： 对内源性调节细胞因子的功能性抗体进行了搜索，重点关注炎性疾病和细胞因子之间的关系。 用人外周血单核细胞部分免疫小鼠，检查获得的抗体的细胞因子调节作用。 结果，在这些抗体中，证实抗体＃33抑制许多典型的炎性细胞因子的产生。 同时检测抗体＃33对IL-10产生的促进作用，揭示抗体＃33具有加速IL-10产生的作用，但没有诱导IL-10过量产生的活性。 该有希望的抗体的抗原被证实为CD61。 因此，可以想到，当抗CD61抗体用于治疗炎性疾病时，它们将成为具有确定功效和高安全性的药物。

    Process For Producing Hematopoietic Stem Cells Or Vascular Endothelial Precursor Cells
    8.
    发明申请
    Process For Producing Hematopoietic Stem Cells Or Vascular Endothelial Precursor Cells 审中-公开
    生产造血干细胞或血管内皮前体细胞的方法

    公开(公告)号：US20080095746A1

    公开(公告)日：2008-04-24

    申请号：US10581393

    申请日：2004-10-29

    申请人： Atsushi Miyajima ,  Masaki Takeuchi ,  Ichiro Yahara ,  Tomoya Okabe ,  Izumi Onitsuka

    发明人： Atsushi Miyajima ,  Masaki Takeuchi ,  Ichiro Yahara ,  Tomoya Okabe ,  Izumi Onitsuka

    IPC分类号： A61K39/00 ,  A61K48/00 ,  A61P35/00 ,  C12N5/00 ,  C12Q1/20

    CPC分类号： C12N5/0692 ,  C12N5/0647 ,  G01N2500/10

    摘要： The present invention provides methods for producing hematopoietic stem cells or vascular endothelial precursor cells, wherein the methods comprise the step of separating PCLP1-positive cells from the hematopoietic tissues of an individual, and then culturing the obtained cells. PCLP1-positive cells obtained from the hematopoietic tissues of an individual can be cultured for a long time, and during culture they produce large quantities of hematopoietic stem cells or vascular endothelial precursor cells. The hematopoietic stem cells or vascular endothelial precursor cells obtainable by the present invention can be utilized for regenerative medicine.

    摘要翻译： 本发明提供了造血干细胞或血管内皮前体细胞的制造方法，其中所述方法包括从个体的造血组织中分离PCLP1阳性细胞，然后培养所获得的细胞。 从个体的造血组织获得的PCLP1阳性细胞可以长时间培养，并且在培养期间产生大量的造血干细胞或血管内皮前体细胞。 通过本发明获得的造血干细胞或血管内皮前体细胞可用于再生医学。